The latest BioE3 policy builds the framework for high-performance biomanufacturing to propel the development and production
GSK and Hengrui Pharma enter agreements to develop up to 12 innovative medicines across Respiratory, Immunology & Inflammation and Oncology
Net profit doubled to Rs. 10.8 crore, with PAT margin expanding by 560 bps to 14.3%, reflecting strong operational execution
Reported EBITDA up by 19% year-on-year with reported EBITDA margin at 25%
During Q1FY26, the company incurred Capex of ~Rs. 48.5 crores mainly towards capacity expansion, backward integration and finished formulation R&D
Plant-based chemistries have an outsized role to play for the HPC sector by meeting demand for good, gentle, and green products
The agreement includes plans for distribution, technology transfer, local manufacturing, new pharmaceutical product development
The Medical Countermeasures Strategy focuses on strengthening the EU’s preparedness for health crises
Lupin and Zentiva sign license and supply agreement for commercializing Certolizumab
Loteprednol Etabonate Ophthalmic Gel, 0.38% is a corticosteroid indicated for the treatment of postoperative inflammation and pain following ocular surgery
Subscribe To Our Newsletter & Stay Updated
